Trade NanoViricides, Inc. - NNVC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0562 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 1.0969 |
| Open* | 1.1169 |
| 1-Year Change* | -29.66% |
| Day's Range* | 1.1169 - 1.1969 |
| 52 wk Range | 1.00-2.00 |
| Average Volume (10 days) | 107.55K |
| Average Volume (3 months) | 793.50K |
| Market Cap | 12.80M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 11.75M |
| Revenue | N/A |
| EPS | -0.77 |
| Dividend (Yield %) | N/A |
| Beta | 1.11 |
| Next Earnings Date | Feb 12, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 28, 2023 | 1.0969 | 0.0900 | 8.94% | 1.0069 | 1.0969 | 1.0069 |
| Nov 27, 2023 | 1.0169 | 0.0200 | 2.01% | 0.9969 | 1.0269 | 0.9969 |
| Nov 24, 2023 | 0.9944 | -0.0425 | -4.10% | 1.0369 | 1.0569 | 0.9944 |
| Nov 22, 2023 | 1.0569 | -0.0100 | -0.94% | 1.0669 | 1.0669 | 1.0369 |
| Nov 21, 2023 | 1.0769 | 0.0000 | 0.00% | 1.0769 | 1.0869 | 1.0769 |
| Nov 20, 2023 | 1.0869 | 0.0200 | 1.87% | 1.0669 | 1.0969 | 1.0569 |
| Nov 17, 2023 | 1.0769 | 0.0300 | 2.87% | 1.0469 | 1.1069 | 1.0469 |
| Nov 16, 2023 | 1.0969 | -0.0700 | -6.00% | 1.1669 | 1.1669 | 1.0669 |
| Nov 15, 2023 | 1.1669 | -0.1400 | -10.71% | 1.3069 | 1.3069 | 1.0569 |
| Nov 14, 2023 | 1.3069 | 0.2000 | 18.07% | 1.1069 | 1.4069 | 1.0869 |
| Nov 13, 2023 | 1.1069 | 0.1100 | 11.03% | 0.9969 | 1.2069 | 0.9969 |
| Nov 10, 2023 | 1.0169 | -0.0400 | -3.78% | 1.0569 | 1.0569 | 0.9969 |
| Nov 9, 2023 | 1.0469 | -0.0200 | -1.87% | 1.0669 | 1.0669 | 1.0069 |
| Nov 8, 2023 | 1.0669 | -0.0100 | -0.93% | 1.0769 | 1.0869 | 1.0569 |
| Nov 7, 2023 | 1.0869 | -0.0400 | -3.55% | 1.1269 | 1.1269 | 1.0869 |
| Nov 6, 2023 | 1.1269 | 0.0600 | 5.62% | 1.0669 | 1.1269 | 1.0669 |
| Nov 3, 2023 | 1.1169 | 0.0400 | 3.71% | 1.0769 | 1.1169 | 1.0669 |
| Nov 2, 2023 | 1.0969 | -0.0100 | -0.90% | 1.1069 | 1.1469 | 1.0869 |
| Nov 1, 2023 | 1.0969 | -0.0100 | -0.90% | 1.1069 | 1.1169 | 1.0969 |
| Oct 31, 2023 | 1.1169 | -0.0300 | -2.62% | 1.1469 | 1.2069 | 1.1069 |
NanoViricides, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, February 7, 2024 | ||
| Time (UTC) 15:00 | Country US
| Event NanoViricides Inc Annual Shareholders Meeting NanoViricides Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, February 12, 2024 | ||
| Time (UTC) 21:00 | Country US
| Event Q2 2024 NanoViricides Inc Earnings Release Q2 2024 NanoViricides Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 8.94347 | 8.1136 | 8.74411 | 7.99646 | 8.65968 |
| Selling/General/Admin. Expenses, Total | 2.55105 | 2.32874 | 2.62957 | 3.30094 | 2.73796 |
| Research & Development | 6.39241 | 5.78486 | 6.11454 | 4.69552 | 5.92172 |
| Operating Income | -8.94347 | -8.1136 | -8.74411 | -7.99646 | -8.65968 |
| Interest Income (Expense), Net Non-Operating | 0.35489 | 0.00674 | -0.07606 | -5.30741 | 0.23524 |
| Other, Net | -0.14267 | 0 | |||
| Net Income Before Taxes | -8.58857 | -8.10686 | -8.82219 | -13.4465 | -8.42444 |
| Net Income After Taxes | -8.58857 | -8.10686 | -8.82219 | -13.4465 | -8.42444 |
| Net Income Before Extra. Items | -8.58857 | -8.10686 | -8.82219 | -13.4465 | -8.42444 |
| Net Income | -8.58857 | -8.10686 | -8.82219 | -13.4465 | -8.42444 |
| Income Available to Common Excl. Extra. Items | -8.58857 | -8.10686 | -8.82219 | -13.4465 | -8.42444 |
| Income Available to Common Incl. Extra. Items | -8.58857 | -8.10686 | -8.82219 | -13.4465 | -8.42444 |
| Diluted Net Income | -8.58857 | -8.10686 | -8.82219 | -13.4465 | -8.42444 |
| Diluted Weighted Average Shares | 11.6262 | 11.5347 | 10.901 | 5.61673 | 3.59007 |
| Diluted EPS Excluding Extraordinary Items | -0.73872 | -0.70282 | -0.8093 | -2.39402 | -2.34659 |
| Diluted Normalized EPS | -0.73872 | -0.70282 | -0.80912 | -2.39402 | -2.34659 |
| Unusual Expense (Income) | 0 | 0 | |||
| Revenue | 0 | 0 | |||
| Total Extraordinary Items | |||||
| Gain (Loss) on Sale of Assets | 0 | -0.00203 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | |||||
| Total Operating Expense | 3.67637 | 1.81074 | 1.83399 | 1.62236 | 1.79278 |
| Selling/General/Admin. Expenses, Total | 0.76342 | 0.61465 | 0.66328 | 0.5097 | 0.62122 |
| Research & Development | 2.91295 | 1.19609 | 1.17071 | 1.11266 | 1.17156 |
| Operating Income | -3.67637 | -1.81074 | -1.83399 | -1.62236 | -1.79278 |
| Interest Income (Expense), Net Non-Operating | 0.10638 | 0.10794 | 0.08886 | 0.05172 | 0.01279 |
| Gain (Loss) on Sale of Assets | 0 | ||||
| Net Income Before Taxes | -3.56999 | -1.7028 | -1.74513 | -1.57064 | -1.78 |
| Net Income After Taxes | -3.56999 | -1.7028 | -1.74513 | -1.57064 | -1.78 |
| Net Income Before Extra. Items | -3.56999 | -1.7028 | -1.74513 | -1.57064 | -1.78 |
| Net Income | -3.56999 | -1.7028 | -1.74513 | -1.57064 | -1.78 |
| Income Available to Common Excl. Extra. Items | -3.56999 | -1.7028 | -1.74513 | -1.57064 | -1.78 |
| Income Available to Common Incl. Extra. Items | -3.56999 | -1.7028 | -1.74513 | -1.57064 | -1.78 |
| Diluted Net Income | -3.56999 | -1.7028 | -1.74513 | -1.57064 | -1.78 |
| Diluted Weighted Average Shares | 11.6667 | 11.636 | 11.6103 | 11.5924 | 11.5576 |
| Diluted EPS Excluding Extraordinary Items | -0.306 | -0.14634 | -0.15031 | -0.13549 | -0.15401 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Diluted Normalized EPS | -0.306 | -0.14634 | -0.15031 | -0.13549 | -0.15401 |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total Current Assets | 8.44529 | 14.4164 | 20.8238 | 13.9857 | 2.82542 |
| Cash and Short Term Investments | 8.14981 | 14.0664 | 20.5167 | 13.7086 | 2.55521 |
| Cash & Equivalents | 8.14981 | 14.0664 | 20.5167 | 13.7086 | 2.55521 |
| Prepaid Expenses | 0.29549 | 0.35002 | 0.3071 | 0.27706 | 0.27021 |
| Total Assets | 16.8999 | 23.4949 | 30.2623 | 23.9143 | 13.4485 |
| Property/Plant/Equipment, Total - Net | 8.10665 | 8.69419 | 9.0849 | 9.54443 | 10.2273 |
| Property/Plant/Equipment, Total - Gross | 14.8097 | 14.658 | 14.3337 | 14.1008 | 14.0922 |
| Accumulated Depreciation, Total | -6.70308 | -5.96382 | -5.24877 | -4.55638 | -3.86493 |
| Intangibles, Net | 0.33358 | 0.34185 | 0.35012 | 0.35839 | 0.36666 |
| Other Long Term Assets, Total | 0.01436 | 0.04244 | 0.00352 | 0.02586 | 0.02919 |
| Total Current Liabilities | 0.53425 | 0.41284 | 0.35115 | 2.15638 | 2.84815 |
| Accounts Payable | 0.39049 | 0.27236 | 0.23156 | 0.94231 | 1.13368 |
| Accrued Expenses | 0.14376 | 0.04569 | 0.02429 | 0.06924 | 0.06887 |
| Notes Payable/Short Term Debt | 0 | 0.09479 | 0.09531 | 1.14483 | 0 |
| Other Current Liabilities, Total | 0 | 1.64561 | |||
| Total Liabilities | 2.03425 | 0.41284 | 0.35115 | 2.15638 | 2.84815 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Other Liabilities, Total | 1.5 | ||||
| Total Equity | 14.8656 | 23.082 | 29.9112 | 21.758 | 10.6004 |
| Preferred Stock - Non Redeemable, Net | 0.00001 | 0.00049 | 0.00037 | 0.00037 | 0.00511 |
| Common Stock | 0.00012 | 0.01159 | 0.01152 | 0.00908 | 0.0769 |
| Additional Paid-In Capital | 145.946 | 145.562 | 144.285 | 127.312 | 102.635 |
| Retained Earnings (Accumulated Deficit) | -131.081 | -122.492 | -114.385 | -105.563 | -92.1166 |
| Total Liabilities & Shareholders’ Equity | 16.8999 | 23.4949 | 30.2623 | 23.9143 | 13.4485 |
| Total Common Shares Outstanding | 11.6985 | 11.5922 | 11.5152 | 9.08341 | 3.84491 |
| Total Preferred Shares Outstanding | 0.54767 | 0.48458 | 0.37149 | 0.3686 | 5.11404 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 7.14311 | 8.44529 | 9.93108 | 11.5529 | 13.1496 |
| Cash and Short Term Investments | 6.96982 | 8.14981 | 9.65096 | 11.4483 | 12.918 |
| Cash & Equivalents | 6.96982 | 8.14981 | 9.65096 | 11.4483 | 12.918 |
| Prepaid Expenses | 0.17328 | 0.29549 | 0.28012 | 0.10455 | 0.23156 |
| Total Assets | 15.4168 | 16.8999 | 18.5768 | 20.335 | 22.0823 |
| Property/Plant/Equipment, Total - Net | 7.92788 | 8.10665 | 8.2909 | 8.41785 | 8.55737 |
| Property/Plant/Equipment, Total - Gross | 14.818 | 14.8097 | 14.8072 | 14.7479 | 14.7025 |
| Accumulated Depreciation, Total | -6.89014 | -6.70308 | -6.51627 | -6.33001 | -6.14516 |
| Intangibles, Net | 0.33151 | 0.33358 | 0.33565 | 0.33771 | 0.33978 |
| Other Long Term Assets, Total | 0.01432 | 0.01436 | 0.01918 | 0.02651 | 0.03559 |
| Total Current Liabilities | 0.94831 | 0.53425 | 0.34874 | 0.46459 | 0.51836 |
| Accounts Payable | 0.60869 | 0.39049 | 0.30658 | 0.41272 | 0.47081 |
| Accrued Expenses | 0.33962 | 0.14376 | 0.04217 | 0.05188 | 0.02371 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0.02384 |
| Total Liabilities | 2.44831 | 2.03425 | 0.34874 | 0.46459 | 0.51836 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 12.9685 | 14.8656 | 18.2281 | 19.8704 | 21.564 |
| Preferred Stock - Non Redeemable, Net | 0.00001 | 0.00001 | 0.0005 | 0.0005 | 0.0005 |
| Common Stock | 0.00012 | 0.00012 | 0.01167 | 0.01163 | 0.01161 |
| Additional Paid-In Capital | 146.018 | 145.946 | 145.727 | 145.666 | 145.615 |
| Retained Earnings (Accumulated Deficit) | -133.049 | -131.081 | -127.511 | -125.808 | -124.063 |
| Total Liabilities & Shareholders’ Equity | 15.4168 | 16.8999 | 18.5768 | 20.335 | 22.0823 |
| Total Common Shares Outstanding | 11.7456 | 11.6985 | 11.6665 | 11.6346 | 11.61 |
| Total Preferred Shares Outstanding | 0.55827 | 0.54767 | 0.49729 | 0.49556 | 0.49517 |
| Other Current Assets, Total | |||||
| Other Liabilities, Total | 1.5 | 1.5 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -8.10686 | -8.82219 | -13.4465 | -8.42444 | -8.56346 |
| Cash From Operating Activities | -5.89125 | -8.21384 | -6.6656 | -6.80277 | -7.77587 |
| Cash From Operating Activities | 0.71506 | 0.69627 | 0.69145 | 0.68764 | 0.67179 |
| Amortization | 0.00827 | 0.00827 | 0.00827 | 0.00827 | 0.00827 |
| Non-Cash Items | 1.27772 | 0.44393 | 5.96155 | 0.35805 | 0.07515 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | |
| Cash Interest Paid | 0.00512 | 0.00486 | 0 | 0 | 0.16667 |
| Changes in Working Capital | 0.21456 | -0.54011 | 0.11966 | 0.56771 | 0.03238 |
| Cash From Investing Activities | -0.32435 | -0.23876 | -0.00864 | -0.07379 | -0.24182 |
| Capital Expenditures | -0.32435 | -0.23876 | -0.00864 | -0.07379 | -0.24182 |
| Other Investing Cash Flow Items, Total | |||||
| Cash From Financing Activities | -0.23472 | 15.2607 | 17.8276 | 2.35 | 0 |
| Issuance (Retirement) of Stock, Net | 0 | 16.5637 | 16.677 | 2.35 | |
| Issuance (Retirement) of Debt, Net | -0.23472 | -1.30301 | 1.16284 | 0 | 0 |
| Net Change in Cash | -6.45032 | 6.80808 | 11.1534 | -4.52656 | -8.01769 |
| Financing Cash Flow Items | -0.01219 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -5.01858 | -3.31578 | -1.57064 | -8.10686 | -6.32687 |
| Cash From Operating Activities | -4.17147 | -2.43338 | -1.03286 | -5.89125 | -4.49355 |
| Cash From Operating Activities | 0.55245 | 0.36619 | 0.18134 | 0.71506 | 0.52917 |
| Amortization | 0.0062 | 0.00414 | 0.00207 | 0.00827 | 0.0062 |
| Non-Cash Items | 0.16461 | 0.10412 | 0.05259 | 1.27772 | 1.17355 |
| Cash Interest Paid | 0.00094 | 0.00094 | 0.00084 | 0.00512 | 0.00349 |
| Changes in Working Capital | 0.12386 | 0.40795 | 0.30179 | 0.21456 | 0.1244 |
| Cash From Investing Activities | -0.14915 | -0.08985 | -0.04451 | -0.32435 | -0.24899 |
| Capital Expenditures | -0.14915 | -0.08985 | -0.04451 | -0.32435 | -0.24899 |
| Cash From Financing Activities | -0.09479 | -0.09479 | -0.07095 | -0.23472 | -0.20201 |
| Issuance (Retirement) of Stock, Net | 0 | 0 | |||
| Issuance (Retirement) of Debt, Net | -0.09479 | -0.09479 | -0.07095 | -0.23472 | -0.1646 |
| Net Change in Cash | -4.4154 | -2.61801 | -1.14832 | -6.45032 | -4.94454 |
| Cash Taxes Paid | 0 | ||||
| Financing Cash Flow Items | 0 | -0.03741 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Theracour Pharma, Inc. | Corporation | 4.0095 | 470959 | 0 | 2022-10-17 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.9027 | 458416 | 0 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.3702 | 160948 | 0 | 2023-06-30 | LOW |
| Compagnie Lombard Odier SCmA | Investment Advisor | 1.277 | 150000 | 0 | 2023-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9475 | 111293 | 0 | 2023-06-30 | LOW |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.8006 | 94039 | 0 | 2023-06-30 | MED |
| Renaissance Technologies LLC | Hedge Fund | 0.6692 | 78600 | 7506 | 2023-06-30 | HIGH |
| Two Sigma Investments, LP | Hedge Fund | 0.3746 | 43996 | 20003 | 2023-06-30 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3568 | 41906 | 0 | 2023-06-30 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.262 | 30777 | 16624 | 2023-06-30 | MED |
| Stifel Nicolaus Investment Advisors | Investment Advisor | 0.1805 | 21200 | 9700 | 2023-06-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1574 | 18494 | 0 | 2023-06-30 | LOW |
| Wharton Business Group, LLC | Investment Advisor | 0.134 | 15736 | 0 | 2023-06-30 | LOW |
| Jawadakar (Makarand) | Individual Investor | 0.0988 | 11604 | 1738 | 2022-10-17 | |
| Rokita (Theodore) | Individual Investor | 0.0941 | 11057 | 1718 | 2022-10-17 | |
| Zucker (Brian) | Individual Investor | 0.0837 | 9834 | 1718 | 2022-10-17 | |
| Vyas (Meeta) | Individual Investor | 0.0626 | 7352 | 223 | 2022-10-17 | |
| Simplex Trading, LLC | Research Firm | 0.0252 | 2964 | -1861 | 2023-06-30 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.0206 | 2420 | 2420 | 2022-10-31 | LOW |
| Osaic Holdings, Inc. | Investment Advisor | 0.0195 | 2285 | 0 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
NanoViricides, Inc. Company profile
About NanoViricides Inc
NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash.
Financial summary
BRIEF: For the six months ended 31 December 2021, NanoViricides Inc revenues was not reported. Net loss decreased 2% to $4.5M. Lower net loss reflects General and administrative decrease of 21% to $1.2M (expense), Interest expense decrease of 96% to $4K (expense), Loss on disposal of property and equip. decrease from $2K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.44 to -$0.39.
Equity composition
Common Stock $.001 Par, 2/11, 300M auth., 139,906,601 issd. Insider owns 30.00%. Conv. Pref. Stock Class A $.001 Par, 10M auth., 7,593,750 issd. 09/13, 1-for-3.5 Reverse Stock split.
| Industry: | Bio Therapeutic Drugs |
1 Controls Drive
SHELTON
CONNECTICUT 06484
US
Income Statement
- Annual
- Quarterly
News
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com